We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Chromocell Therapeutics Corporation, a clinical-stage biotech company, focuses on the discovery, development, and commercialization of new therapeutics to alleviate pain. The company intends to selectively target the sodium ion-channel known as NaV1.7, as well as other receptors in the NaV family. I... Chromocell Therapeutics Corporation, a clinical-stage biotech company, focuses on the discovery, development, and commercialization of new therapeutics to alleviate pain. The company intends to selectively target the sodium ion-channel known as NaV1.7, as well as other receptors in the NaV family. Its lead compound comprises CC8464, which is in Phase 2a clinical trials for use in the treatment of erythromelalgia, as well as other fields of neuropathic pain. Chromocell Therapeutics Corporation was founded in 2002 and is based in Freehold, New Jersey. Show more
FREEHOLD, N.J., July 15, 2024 (GLOBE NEWSWIRE) -- Chromocell Therapeutics Corporation (“Chromocell”, or the “Company”), (NYSE American: CHRO), a pioneer in the development of non-opioid pain...
FREEHOLD, N.J., May 13, 2024 (GLOBE NEWSWIRE) -- Chromocell Therapeutics Corporation (“Chromocell”, or the “Company”), (NYSE American: CHRO), a pioneer in the development of non-opioid pain...
FREEHOLD, N.J., April 09, 2024 (GLOBE NEWSWIRE) -- Chromocell Therapeutics Corporation (“Chromocell”, or the “Company”), (NYSE American: CHRO), a pioneer in the development of non-opioid pain...
FREEHOLD, N.J., March 21, 2024 (GLOBE NEWSWIRE) -- Chromocell Therapeutics Corp. (“Chromocell”, or the “Company”), (NYSE American: CHRO), a pioneer in the development of non-opioid pain...
FREEHOLD, N.J., March 18, 2024 (GLOBE NEWSWIRE) -- Chromocell Therapeutics Corp. (“Chromocell”, or the “Company”), (NYSE American: CHRO), a pioneer in the development of non-opioid pain...
AUSTIN, Texas, March 11, 2024 (GLOBE NEWSWIRE) -- Chromocell Therapeutics Corp. (“Chromocell”, or the “Company”), (NYSE American: CHRO), a pioneer in the development of non-opioid pain treatment...
AUSTIN. Texas, Feb. 27, 2024 (GLOBE NEWSWIRE) -- Benuvia Operations, LLC (“Benuvia”), a leader in pharmaceutical innovation, and Chromocell Therapeutics Corp. (“Chromocell”), (NYSE American:...
Period | Change | Change % | Open | High | Low | Avg. Daily Vol | VWAP | |
---|---|---|---|---|---|---|---|---|
1 | 0.1625 | 20.3659606467 | 0.7979 | 0.9797 | 0.6942 | 13630 | 0.85916003 | CS |
4 | -0.4496 | -31.8865248227 | 1.41 | 1.75 | 0.585 | 27000 | 1.07446495 | CS |
12 | -2.6196 | -73.1731843575 | 3.58 | 3.68 | 0.585 | 23840 | 1.59831613 | CS |
26 | -5.0396 | -83.9933333333 | 6 | 6 | 0.585 | 24847 | 1.98901137 | CS |
52 | -5.0396 | -83.9933333333 | 6 | 6 | 0.585 | 24847 | 1.98901137 | CS |
156 | -5.0396 | -83.9933333333 | 6 | 6 | 0.585 | 24847 | 1.98901137 | CS |
260 | 0 | 0 | 0 | 0.9797 | 0 | 0 | 0 | CS |
Symbol | Price | Vol. |
---|---|---|
SOXLDirexion Daily Semiconductor Bull 3X Shares | US$ 32.61 (1.21%) | 1.31M |
SOXSDirexion Daily Semiconductor Bear 3X Shares New | US$ 23.93 (-0.95%) | 626.41k |
ITPIT Tech Packaging Inc | US$ 0.2811 (11.64%) | 561.52k |
NVDQT Rex 2X Inverse NVIDIA Daily Target ETF | US$ 5.03 (-1.76%) | 456.8k |
NVDXT Rex 2X Long NVIDIA Daily Target ETF | US$ 13.52 (1.96%) | 243.26k |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions